FDA has accepted Replimune’s RP1 resubmission for advanced melanoma treatment. ・Prescription Drug User Fee Act decision date ...

NEW YORK, NY, NY / ACCESS Newswire / October 20, 2025 / At Utah's White Mesa Mill, the smell of acid and ambition hangs in the air. Giant bags of monazite ore, each weighing more than a car, are ...

VANCOUVER, BC / ACCESS Newswire / October 20, 2025 / Empress Royalty Corp. ("Empress Royalty" or the "Company") is pleased to announce the appointment of Daniel Burns, JD, MBA, CPA, ...

The challenge with curing the Human Immunodeficiency Virus (HIV) is that it tends to hide dormant in cells, evading the ...

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the ...

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ...

The antibody, called 04_A06, blocked 98.5% of more than 300 different HIV strains in lab tests, including many resistant to ...

A drug that harnesses the immune system to attack cancer cells has proved successful in preventing a rare and aggressive form ...

When immune cells strike, precision is everything. New research reveals how natural killer and T cells orchestrate the release of toxic granules – ...

According to the new study, HIV achieves this with a tissue-specific approach, cloaking itself in a host cell's DNA by ...

A groundbreaking study reveals that cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting ...